Get the Stockscreener App
11.07
3.40%
-0.39
After Hours:
11.07
Delcath Systems Inc stock is traded at $11.07, with a volume of 550.64K.
It is down -3.40% in the last 24 hours and up +0.73% over the past month.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$11.46
Open:
$11
24h Volume:
550.64K
Relative Volume:
1.36
Market Cap:
$382.15M
Revenue:
$85.23M
Net Income/Loss:
$2.70M
P/E Ratio:
176.27
EPS:
0.0628
Net Cash Flow:
$20.97M
1W Performance:
-3.57%
1M Performance:
+0.73%
6M Performance:
+23.96%
1Y Performance:
-31.03%
1-Day Range:
$10.87
$11.32
1-Week Range:
$10.79
$11.72
52-Week Range:
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
11.07 | 395.62M | 85.23M | 2.70M | 20.97M | 0.0628 |
ABT
Abbott Laboratories
|
84.47 | 147.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
306.76 | 117.12B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.15 | 98.82B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
52.68 | 79.59B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.38 | 46.84B | 6.30B | 1.07B | 1.09B | 1.8406 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Implied volatility surging for Delcath Systems stock options - MSN
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Daily Tribune News
Delcath Systems announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Delcath hires receive 24,500 stock units over 3 years - Stock Titan
Delcath Systems (DCTH) director receives grant of 22,500 stock options at $11.61 - Stock Titan
Delcath Systems (NASDAQ: DCTH) director receives 22,500 stock options at $11.61 strike - Stock Titan
Delcath Systems (DCTH) director awarded 22,500 stock options at $11.61 - Stock Titan
Director at Delcath (NASDAQ: DCTH) awarded 22,500 stock options - Stock Titan
Delcath (DCTH) awards director 22,500 options at $11.61 strike - Stock Titan
Delcath Systems, Inc. 8-K Filing May 13, 2026 – Company Information, Equity Incentive Plan, and SEC Compliance 212 - Minichart
Delcath Shareholders Approve Expanded Equity Plan and Governance - TipRanks
Delcath Systems shareholders approve equity plan amendment and board elections By Investing.com - Investing.com South Africa
Delcath Systems shareholders approve equity plan amendment and board elections - Investing.com
Delcath (NASDAQ: DCTH) approves 1.8M-share boost to 2020 equity plan - Stock Titan
Earnings call transcript: Delcath Systems Q1 2026 beats EPS forecast, stock rises - Investing.com Canada
Liver cancer-focused Delcath heads to Nasdaq BioConnect investor conference May 19 - Stock Titan
TradingKey - TradingKey
Delcath Systems Q1 2026: -$0.03 EPS Tops Estimates — Deep Dive - AlphaStreet
Tangible book value per share of Delcath Systems, Inc. – SWB:DV3R - TradingView
Delcath Systems Balances Growth with Rising Costs - The Globe and Mail
MSN Money - MSN
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results - MarketBeat
Q1 2026 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Delcath Systems, Inc. (DCTH) Stock Analysis: Aiming for an 89.80% Upside in the Medical Device Sector - DirectorsTalk Interviews
Uveal Melanoma Treatment Market is expected to Hit US$ 2.7 - openPR.com
Delcath Systems Reports First Quarter 2026 Results and Business Highlights - BioSpace
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 - BioSpace
Number of shareholders of Delcath Systems, Inc. – DUS:DV3R - TradingView
Delcath Systems, Inc. (DCTH) reports Q1 loss, misses revenue estimates - MSN
Delcath Systems Q1 Earnings Call Highlights - MarketBeat
Delcath Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
DCTH: Q1 saw record patient starts, 36% volume growth, and strong 2026 revenue guidance - TradingView
Delcath presents data on liver cancer treatment in breast cancer patients By Investing.com - Investing.com South Africa
Delcath presents data on liver cancer treatment in breast cancer patients - Investing.com UK
Delcath Systems Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Delcath Systems (NASDAQ:DCTH) Surpasses Q1 Estimates, Guidance Points to Continued Growth - ChartMill
Delcath Systems | 10-Q: Q1 2026 Earnings Report - Moomoo
Delcath Systems (NASDAQ: DCTH) grows Q1 2026 sales but posts small loss - Stock Titan
DELCATH SYSTEMS ($DCTH) Releases Q1 2026 Earnings - Quiver Quantitative
Delcath (NASDAQ: DCTH) Q1 revenue hits $25M with 2026 outlook of $100M+ - Stock Titan
Delcath Systems Sees Positive Adjusted EBITDA for 2026 >DCTH - Moomoo
Cancer treatment company targets $100M sales with 29 centers active - Stock Titan
A liver-targeted breast cancer procedure drew new data at ESMO - Stock Titan
Delcath Systems Q1 2026 Earnings Call Transcript - MarketBeat
Delcath Systems Q1 2026 earnings preview - MSN
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Delcath Systems Inc Stock (DCTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sylvester John Richard | Director |
Nov 21 '25 |
Buy |
8.89 |
4,386 |
38,992 |
14,936 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER |
Nov 11 '25 |
Buy |
8.53 |
11,500 |
98,049 |
330,834 |
| Vukovic Vojo | CHIEF MEDICAL OFFICER |
Jun 12 '25 |
Option Exercise |
4.78 |
42,000 |
200,760 |
168,882 |
1.27%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):